Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Parker, Christopher; D. James, Nicholas; Brawley, Chris; W. Clarke, Noel; Hoyle, Alex; Ali, Adnan; Ritchie, A.W.S.; Attard, Gerhardt; Chowdhury, Simon; Cross, William; P. Dearnaley, David; Gillessen, Silke; Gilson, Clare; J. Jones, Robert; E. Langley, Ruth; Malik, Zafar; D. Mason, Malcolm; Matheson, David; Millman, Robin; M. Russell, John; N. Thalmann, George; Amos, Claire; Alonzi, Roberto; Bahl, Amit; Birtle, Alison; Din, Omar; Douis, Hassan; Eswar, Chinnamani; Gale, Joanna; Gannon, Melissa; Jonnada, Sai; Khaksar, Sara; Lester, J.F.; M. O’Sullivan, Joe; Parikh, Omi; Pedley, Ian; Pudney, Delia; Sheehan, D.J.; Srihari, Narayanan; Tran, Anna; Parmar, Mahesh; R. Sydes, Matthew

doi:10.1016/s0140-6736(18)32486-3

Public

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Published in The Lancet • Oct 21, 2018

Authors:

Christopher Parker

Nicholas D. James

Chris Brawley

Abstract

BACKGROUND: Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prosta...

Subject

Medicine

Prostate cancer

Radiation therapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!